New antibody therapy shows promise for Hard-to-Treat myeloma
NCT ID NCT04557098
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called teclistamab in people with multiple myeloma that has come back or stopped responding to treatment. The drug is a special antibody that helps the body's immune cells find and attack cancer cells. About 194 participants will receive the drug to see how well it shrinks tumors and how long the effect lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teclistamab (a bispecific antibody that helps immune cells attack myeloma cells)
What this could lead to
If successful, this could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is an early-phase trial with a small number of participants. The drug may not work for everyone, and side effects like immune reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2, Canada
-
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, 24127, Italy
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
C.H.U. Hotel Dieu - France
Nantes, 44093, France
-
CHRU Hôpital Bretonneau
Tours, 37044, France
-
CHU Poitiers - Hopital la Miletrie
Poitiers, 86000, France
-
Centre Hospitalier Lyon Sud
Lyon, 69002, France
-
Centre Hospitalier Régional Universitaire de Lille, Hôpital Claude Huriez
Lille, 59000, France
-
City of Hope
Duarte, California, 91010, United States
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
First affiliated Hospital of Zhejiang University
Hangzhou, 310003, China
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Haematology Centre, R 51
Stockholm, SE-141 86, Sweden
-
Hosp Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp. Quiron Madrid Pozuelo
Pozuelo de Alarcón, 28223, Spain
-
Hosp. Univ. 12 de Octubre
Madrid, 28041, Spain
-
Hosp. Univ. Germans Trias I Pujol
Badalona, 08916, Spain
-
Hosp. Univ. Marques de Valdecilla
Santander, 39008, Spain
-
Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects
New York, New York, 10029, United States
-
Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi
Bologna, 40138, Italy
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
McGill University Health Centre
Montreal, Quebec, H4A 3J1, Canada
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Peking University First Hospital
Beijing, 100034, China
-
Pôle IUC Oncopole CHU
Toulouse, 31059, France
-
Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
-
Sahlgrenska University Hospital
Gothenburg, 413 45, Sweden
-
Shanghai Changzheng Hospital
Shanghai, 200003, China
-
Shengjing Hospital Of China Medical University
Shenyang, 110134, China
-
Skane University Hospital
Lund, 221 85, Sweden
-
Stanford University Medical Center
Stanford, California, 94305-5623, United States
-
Sun Yat -Sen University Cancer Center
Guangzhou, 510060, China
-
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, 710004, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, 30060, China
-
Universitaetsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitaetsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,
Tübingen, 72076, Germany
-
Universitair Ziekenhuis Gent - UZ GENT
Ghent, 9000, Belgium
-
Universitaire Ziekenhuizen Leuven
Leuven, 3000, Belgium
-
Universitatsklinikum Wurzburg
Würzburg, 97080, Germany
-
University College Hospital
London, NW1 2PG, United Kingdom
-
University Health Network UHN Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
University Hospital Southampton
Sothampton, SO16 6YD, United Kingdom
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
VU Medisch Centrum
Amsterdam, 1081 HV, Netherlands
-
West China Hospital Si Chuan University
Chengdu, 610041, China
-
Winship Cancer Institute Emory University
Atlanta, Georgia, 30322, United States